“…One question that comes into mind is whether this lack of effectiveness is specific for the HPV-positive fraction of OPSCC/HNSCC tumors, which clearly have a different biology than HPV-negative. Focusing on prospective trials with mostly HPV-negative tumors, cetuximab failed to enhance survival when added to chemoradiation in RTOG-0522 and when added to induction chemotherapy and subsequent RT in DeLOS-II [16] , [17] . Furthermore, the alternative anti-EGFR antibodies panitumumab (CONCERT-1&2) and zalutumumab (DAHANCA 19) also failed to compete with cisplatin when added to RT or to enhance survival when added to chemoradiation, as well as the EGFR-inhibitor erlotinib [18] , [19] , [20] , [21] .…”